183 filings
Page 4 of 10
6-K
EVAX
Evaxion Biotech A/S
5 Jun 23
Current report (foreign)
7:44am
6-K
EVAX
Evaxion Biotech A/S
31 May 23
Evaxion Announces Business Update and First Quarter 2023 Financial Results
8:36am
6-K
EVAX
Evaxion Biotech A/S
25 May 23
Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines
4:55pm
6-K
EVAX
Evaxion Biotech A/S
25 May 23
Evaxion announces promising clinical Phase 1 data
4:55pm
6-K
EVAX
Evaxion Biotech A/S
4 May 23
Notice of Annual General Meeting
4:45pm
20-F
2022 FY
EVAX
Evaxion Biotech A/S
Annual report (foreign)
27 Apr 23
8:56pm
6-K
EVAX
Evaxion Biotech A/S
27 Apr 23
Fourth quarter and full year 2022 financial results and business update
8:30am
6-K
EVAX
Evaxion Biotech A/S
18 Apr 23
Current report (foreign)
9:19am
6-K
EVAX
Evaxion Biotech A/S
18 Apr 23
Current report (foreign)
8:00am
6-K
EVAX
Evaxion Biotech A/S
28 Mar 23
Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients
9:05am
6-K
EVAX
Evaxion Biotech A/S
23 Mar 23
Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients
8:53am
6-K
EVAX
Evaxion Biotech A/S
22 Mar 23
Current report (foreign)
4:45pm
6-K
EVAX
Evaxion Biotech A/S
24 Feb 23
Current report (foreign)
4:45pm
6-K
EVAX
Evaxion Biotech A/S
6 Feb 23
Current report (foreign)
4:45pm
6-K
EVAX
Evaxion Biotech A/S
2 Feb 23
Notice of Extraordinary General Meeting
4:45pm
6-K/A
EVAX
Evaxion Biotech A/S
20 Jan 23
Current report (foreign) (amended)
4:45pm
6-K
EVAX
Evaxion Biotech A/S
19 Jan 23
Evaxion receives FDA fast-track designation for personalized cancer immunotherapy
8:45am
6-K
EVAX
Evaxion Biotech A/S
29 Dec 22
Current report (foreign)
5:00pm
6-K
EVAX
Evaxion Biotech A/S
27 Dec 22
Current report (foreign)
5:17pm
6-K/A
EVAX
Evaxion Biotech A/S
27 Dec 22
Current report (foreign) (amended)
7:22am